Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 11Triple Negative Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × Mastectomy × Clear all
NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
67 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01234532 2022-05-03

0927GCC

University of Maryland, Baltimore

Phase 2 Terminated
5 enrolled 7 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡